Zobrazeno 1 - 10
of 39
pro vyhledávání: '"Gian Carlo Antonini Cappellini"'
Autor:
Lauretta Levati, Claudio Tabolacci, Antonio Facchiano, Francesco Facchiano, Ester Alvino, Gian Carlo Antonini Cappellini, Enrico Scala, Laura Bonmassar, Simona Caporali, Pedro Miguel Lacal, Antonella Bresin, Federica De Galitiis, Giandomenico Russo, Stefania D’Atri
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 43, Iss 1, Pp 1-19 (2024)
Abstract Background Circulating cytokines can represent non-invasive biomarkers to improve prediction of clinical outcomes of cancer patients. Here, plasma levels of IL-8, CCL4, osteopontin, LIF and BDNF were determined at baseline (T0), after 2 mont
Externí odkaz:
https://doaj.org/article/a0bdc7a211eb48ef9b02d1cc5e1b8897
Autor:
Mariele Bevilaqua, Maria Carolina Widholzer Rey, Gian Carlo Antonini Cappellini, Felice Riccardi, Cristina Fortes, Adriana Vial Roehe, Renan Rangel Bonamigo
Publikováno v:
Anais Brasileiros de Dermatologia, Vol 98, Iss 6, Pp 793-798 (2023)
Abstract Background In cutaneous melanomas in general, tumor inflammatory infiltrate (TII) can protect against distant metastases, but there is no consensus when only thin primary cutaneous melanomas (TPCM) are considered. Objective To investigate th
Externí odkaz:
https://doaj.org/article/f77cf5ce3bd446338eabd0684bc0f37d
Autor:
Federica Ruffini, Claudia Ceci, Maria Grazia Atzori, Simona Caporali, Lauretta Levati, Laura Bonmassar, Gian Carlo Antonini Cappellini, Stefania D’Atri, Grazia Graziani, Pedro Miguel Lacal
Publikováno v:
Pharmacological Research, Vol 192, Iss , Pp 106782- (2023)
Melanoma resistance to BRAF inhibitors (BRAFi) is often accompanied by a switch from a proliferative to an invasive phenotype. Therefore, the identification of signaling molecules involved in the development of metastatic properties by resistant mela
Externí odkaz:
https://doaj.org/article/8a4322fd7f85473abdc2bd80fa190bb0
Autor:
Sabrina Chiloiro, Antonella Giampietro, Antonio Bianchi, Sara Menotti, Flavia Angelini, Tommaso Tartaglione, Gian Carlo Antonini Cappellini, Federica De Galitiis, Ernesto Rossi, Giovanni Schinzari, Alessandro Scoppola, Alfredo Pontecorvi, Laura De Marinis, Maria Fleseriu
Publikováno v:
Journal of Personalized Medicine, Vol 13, Iss 3, p 415 (2023)
Background: Immune checkpoint inhibitor hypophysitis (IIHs) is an emerging problem in cancer patients treated with immune checkpoint inhibitors (ICIs). We aimed to describe the clinical and molecular features of a multicenter series of IIHs. Methods:
Externí odkaz:
https://doaj.org/article/168e196cb4f74a1b8c59801d377b7ba1
Autor:
Lauretta Levati, Cristian Bassi, Simona Mastroeni, Laura Lupini, Gian Carlo Antonini Cappellini, Laura Bonmassar, Ester Alvino, Simona Caporali, Pedro Miguel Lacal, Maria Grazia Narducci, Ivan Molineris, Federica De Galitiis, Massimo Negrini, Giandomenico Russo, Stefania D’Atri
Publikováno v:
Cancers, Vol 14, Iss 15, p 3706 (2022)
Despite the significant improvements in advanced melanoma therapy, there is still a pressing need for biomarkers that can predict patient response and prognosis, and therefore support rational treatment decisions. Here, we investigated whether circul
Externí odkaz:
https://doaj.org/article/e39091af471049918650cd5a73305b40
Autor:
Simona Caporali, Adriana Amaro, Lauretta Levati, Ester Alvino, Pedro Miguel Lacal, Simona Mastroeni, Federica Ruffini, Laura Bonmassar, Gian Carlo Antonini Cappellini, Nadia Felli, Alessandra Carè, Ulrich Pfeffer, Stefania D’Atri
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 38, Iss 1, Pp 1-24 (2019)
Abstract Background Development of resistance to inhibitors of BRAF (BRAFi) and MEK (MEKi) remains a great challenge for targeted therapy in patients with BRAF-mutant melanoma. Here, we explored the role of miRNAs in melanoma acquired resistance to B
Externí odkaz:
https://doaj.org/article/ad44b34751c2441eb4d91f50e0307725
Autor:
Giuseppe Minniti, Dimitri Anzellini, Chiara Reverberi, Gian Carlo Antonini Cappellini, Luca Marchetti, Federico Bianciardi, Alessandro Bozzao, Mattia Osti, Pier Carlo Gentile, Vincenzo Esposito
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Purpose To investigate the efficacy and safety of concurrent stereotactic radiosurgery (SRS) and ipilimumab or nivolumab in patients with untreated melanoma brain metastases. Patients and Methods Eighty consecutive patients with 326 melanoma
Externí odkaz:
https://doaj.org/article/71ed64b533a64663b16c816ac3911543
Autor:
Alessio Cortellini, Melissa Bersanelli, Sebastiano Buti, Katia Cannita, Daniele Santini, Fabiana Perrone, Raffaele Giusti, Marcello Tiseo, Maria Michiara, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Federica Zoratto, Enzo Veltri, Riccardo Marconcini, Francesco Malorgio, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Federica Pergolesi, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Rita Chiari, Biagio Ricciuti, Andrea De Giglio, Daniela Iacono, Alain Gelibter, Mario Alberto Occhipinti, Alessandro Parisi, Giampiero Porzio, Maria Concetta Fargnoli, Paolo Antonio Ascierto, Corrado Ficorella, Clara Natoli
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-11 (2019)
Abstract Background Recent evidence suggested a potential correlation between overweight and the efficacy of immune checkpoint inhibitors (ICIs) in cancer patients. Patients and methods We conducted a retrospective study of advanced cancer patients c
Externí odkaz:
https://doaj.org/article/721f0d0be9e345b393f57f040b3f9b1c
Autor:
Maria Grazia Narducci, Anna Tosi, Alessandra Frezzolini, Enrico Scala, Francesca Passarelli, Laura Bonmassar, Alessandro Monopoli, Maria Pina Accetturi, Maria Cantonetti, Gian Carlo Antonini Cappellini, Federica De Galitiis, Antonio Rosato, Mario Picozza, Giandomenico Russo, Stefania D’Atri
Publikováno v:
Frontiers in Immunology, Vol 11 (2020)
Despite the recent availability of several new drugs in hemato-oncology, T-cell lymphomas are still incurable and PD-1 blockade could represent a therapeutic chance for selected patients affected by these malignancies, although further studies are re
Externí odkaz:
https://doaj.org/article/1c8fc2a673d54b849a6b8725c0c206c0
Autor:
Alessio Cortellini, Sebastiano Buti, Melissa Bersanelli, Raffaele Giusti, Fabiana Perrone, Pietro Di Marino, Nicola Tinari, Michele De Tursi, Antonino Grassadonia, Katia Cannita, Alessandra Tessitore, Federica Zoratto, Enzo Veltri, Francesco Malorgio, Marco Russano, Cecilia Anesi, Tea Zeppola, Marco Filetti, Paolo Marchetti, Andrea Botticelli, Gian Carlo Antonini Cappellini, Federica De Galitiis, Maria Giuseppa Vitale, Francesca Rastelli, Federica Pergolesi, Rossana Berardi, Silvia Rinaldi, Marianna Tudini, Rosa Rita Silva, Annagrazia Pireddu, Francesco Atzori, Daniela Iacono, Maria Rita Migliorino, Alain Gelibter, Mario Alberto Occhipinti, Francesco Martella, Alessandro Inno, Stefania Gori, Sergio Bracarda, Cristina Zannori, Claudia Mosillo, Alessandro Parisi, Giampiero Porzio, Domenico Mallardo, Maria Concetta Fargnoli, Marcello Tiseo, Daniele Santini, Paolo A Ascierto, Corrado Ficorella
Publikováno v:
OncoImmunology, Vol 9, Iss 1 (2020)
Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cance
Externí odkaz:
https://doaj.org/article/4699db3802134eacb6e95731df7e4bdc